Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Cancer Res. 2017 Nov 27;78(1):246–255. doi: 10.1158/0008-5472.CAN-17-1973

Figure 3. BGB324 in combination with gemcitabine inhibits cell survival and epithelial plasticity.

Figure 3

A) Tumor tissue from KIC mice treated with BGB324 +/− gemcitabine was evaluated by immunofluorescence for cleaved-caspase 3, phospho-histone-3, endomucin, E-cadherin, and vimentin. Images were analyzed using Elements software; quantification of % area fraction is shown. Data are displayed as mean ± SD and represent 5 images per tumor with 4 animals per group analyzed. *P < 0.05; **P < 0.01; ***P < 0.005; by ANOVA with Tukey’s MCT. B) Lysates of tumors from KIC animals treated with BGB324 +/− gemcitabine were probed for the indicated targets by Western blotting. C) Tumor tissue from KIC animals treated with BGB324 +/− gemcitabine was evaluated by immunohistochemistry for the expression level of equilibrative nucleoside transporter 1 (ENT1). Quantification of % area fraction is shown. Scale bar, 100 μM.